Will Keflex (cephalexin) treat E. coli infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Keflex (cephalexin) is not the most recommended treatment for E. coli infections due to varying resistance rates, and its use should be guided by local antimicrobial susceptibility patterns and individual patient factors. When considering treatment for E. coli infections, particularly those affecting the urinary tract, it's crucial to take into account the antimicrobial resistance patterns of the specific region and the individual patient's history with antibiotics [ 1 ]. The resistance rates of E. coli to various antimicrobials, including first- and second-generation oral cephalosporins like cephalexin, can vary significantly by geographic location [ 1 ]. While cephalexin may be effective against some E. coli strains, its efficacy can be compromised in areas with high resistance rates, making it essential to consider alternative antimicrobials such as nitrofurantoin, fosfomycin, or mecillinam, which have shown good in vitro activity against E. coli in various regions [ 1 ]. Key factors to consider in the choice of antimicrobial include the patient's recent travel history, previous use of antimicrobials, and local resistance patterns [ 1 ]. Given the potential for resistance and the importance of effective treatment, susceptibility testing is recommended for complicated or recurrent E. coli infections to guide the selection of the most appropriate antimicrobial therapy. In cases where cephalexin is deemed appropriate based on susceptibility testing, the typical adult dosage for uncomplicated urinary tract infections is 250-500 mg taken orally every 6 hours, or 500 mg every 12 hours, for 7-14 days depending on infection severity [ 1 ]. However, the decision to use cephalexin should always prioritize the most recent and highest quality evidence available, considering morbidity, mortality, and quality of life outcomes.

From the Research

Keflex and E. coli Infections

  • Keflex, also known as cephalexin, is a semisynthetic cephalosporin antibiotic used to treat various bacterial infections 2.
  • The antimicrobial spectrum of cephalexin includes pathogens commonly encountered in clinical practice, such as those causing upper and lower respiratory tract, skin and soft tissue, and genitourinary tract infections 2.
  • Cephalexin is effective against many urinary tract pathogens, with concentrations in urine many times greater than the minimum inhibitory concentration for these pathogens 2, 3.

Efficacy Against E. coli

  • E. coli is a common cause of urinary tract infections, and cephalexin has been shown to be effective in treating these infections 2, 3.
  • Studies have demonstrated that cephalexin can achieve high concentrations in urine, making it effective against E. coli and other urinary tract pathogens 2.
  • However, the effectiveness of cephalexin against E. coli can depend on various factors, such as the severity of the infection and the presence of any underlying medical conditions 2, 3.

Important Considerations

  • Cephalexin is not effective against all types of bacteria, and its use should be guided by culture and sensitivity testing to ensure that the causative organism is susceptible to the antibiotic 2, 3.
  • Patients with creatinine clearances less than 30 ml/min may require a reduction in cephalexin dosage, which should be proportional to the reduced function 2.
  • Cephalexin can cause adverse effects, such as gastrointestinal upset, rash, and urticaria, although these are relatively infrequent and usually do not require discontinuance of the drug 4, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

The pharmacology of cephalexin.

Postgraduate medical journal, 1983

Research

Cephalexin in lower respiratory tract infections.

Postgraduate medical journal, 1983

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.